20:21 , Mar 30, 2018 |  BioCentury  |  Product Development

Perception into pain

Against the backdrop of the snowballing opioid crisis, drugmakers are aiming to get new therapies to patients faster by making pain trials more efficient and lower risk. New patient stratification methods are contributing to the...
02:06 , Feb 22, 2017 |  BC Week In Review  |  Clinical News

MOR107: Ph I started

MorphoSys said its Lanthio Pharma B.V. subsidiary began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate single ascending doses of subcutaneous MOR107 in 80-110 healthy male volunteers. MorphoSys AG (Xetra:MOR; Pink:MPSYY), Martinsried, Germany  Product:...
07:00 , Sep 14, 2015 |  BioCentury  |  Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Spinifex, Novartis deal

Novartis will acquire chronic pain treatment developer Spinifex for $200 million up front. Spinifex shareholders will be eligible for undisclosed milestones under the deal, which is expected to close this half. Spinifex’s lead candidate is...
02:16 , Jun 30, 2015 |  BC Extra  |  Company News

Novartis acquires pain play Spinifex

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire chronic pain treatment developer Spinifex Pharmaceuticals Pty. Ltd. (Preston, Australia) for $200 million up front. Spinifex shareholders are eligible for undisclosed milestones. The companies expect the deal to close...
07:00 , Jun 11, 2015 |  BC Innovations  |  Translation in Brief

Taming toxins for pain

Scientists at the Pasteur Institute have created a pain therapeutic from an ulcer-causing toxin by removing a functional group responsible for its toxic properties and leaving intact the core molecule with analgesic and anti-inflammatory activity....
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

Lanthio Pharma, MorphoSys deal

MorphoSys acquired the remaining 80% of Lanthio it did not already own for EUR20 million ($22.3 million). MorphoSys gains LP2 , a selective angiotensin II type 2 (AT2) receptor (ATGR2) agonist lantipeptide, which MorphoSys renamed...
02:17 , May 8, 2015 |  BC Extra  |  Company News

MorphoSys acquires Lanthio

MorphoSys AG (Xetra:MOR; Pink:MPSYF) said it will acquire all the shares it does not already own of Lanthio Pharma B.V. (Groningen, the Netherlands) for EUR 20 million ($22.3 million). MorphoSys, which invested in Lanthio's series...
01:50 , Apr 24, 2015 |  BC Extra  |  Company News

Novartis hunting for $2-$5B acquisitions

After closing its $16 billion asset swap with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Novartis AG (NYSE:NVS; SIX:NOVN) said on its 1Q15 earnings call Thursday that it is seeking bolt-on acquisitions on the order of $2-$5 billion...
08:00 , Feb 19, 2015 |  BC Innovations  |  Targets & Mechanisms

Ace of hearts

Less than two years after coming out of stealth mode, University of Washington spinout Beat BioTherapeutics Corp. has shown preclinical proof of concept for its heart failure gene therapy designed to provide dATP as an...